title: DNA damage stress and inhibition of Jak2-V617F cause its degradation and synergistically induce apoptosis through activation of GSK3β.
abstract: The cytoplasmic tyrosine kinase Jak2 plays a crucial role in cytokine receptor signaling in hematopoietic cells. The activated Jak2-V617F mutant is present in most cases of BCR/ABL-negative myeloproliferative neoplasms and constitutively activates downstream signals from homodimeric cytokine receptors, such as the erythropoietin receptor (EpoR). Here we examine the effects of DNA damage stress on Jak2 or Jak2-V617F and on induction of apoptosis in hematopoietic cells. Etoposide or doxorubicin dose-dependently decreased the expression level of Jak2 in UT7 or 32D cells expressing EpoR in the absence of Epo and that of exogenously expressed Jak2-V617F in UT7 cells when cotreated with the Jak2 inhibitor JakI-1 or AG490. Studies with pharmacological inhibitors and genetic manipulations further showed that downregulation of the PI3K/Akt pathway leading to the activation of GSK3β may be involved in downregulation of Jak2 or Jak2-V617F as well as in synergistic induction of Bax activation and apoptosis. The downregulation of Jak2 was inhibited by the proteasome inhibitor MG132 or by expression of both of loss-of-function mutants of c-Cbl and Cbl-b, E3 ubiquitin ligases which facilitated ubiquitination of Jak2-V617F when co-expressed in 293T cells. The pan-caspase inhibitor Boc-d-fmk also inhibited the Jak2 downregulation as well as appearance of a 100-kDa fragment that contained the N-terminal portion of Jak2 in response to DNA damage. Together, these data suggest that DNA damage stress with simultaneous inhibition of the kinase activity causes degradation of Jak2 or Jak2-V617F by caspase cleavage and proteasomal degradation through GSK3β activation, which is closely involved in synergistic induction of apoptosis in hematopoietic cells.
authors.affiliation: Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
authors.forename: Toshikage
authors.initials: T
authors.lastname: Nagao
authors.forename: Gaku
authors.initials: G
authors.lastname: Oshikawa
authors.forename: Nan
authors.initials: N
authors.lastname: Wu
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Kurosu
authors.forename: Osamu
authors.initials: O
authors.lastname: Miura
mesh_terms: D017209:Apoptosis; D020169:Caspases / Q000378:metabolism; D002460:Cell Line; D004249:DNA Damage; D010450:Endopeptidases / Q000378:metabolism; D004789:Enzyme Activation; D038362:Glycogen Synthase Kinase 3 / Q000378:metabolism*; D000071679:Glycogen Synthase Kinase 3 beta; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors* / Q000235:genetics; D020125:Mutation, Missense; D059748:Proteolysis
chemical_list: D053614:Janus Kinase 2; C000605506:GSK3B protein, human; D000071679:Glycogen Synthase Kinase 3 beta; D038362:Glycogen Synthase Kinase 3; D010450:Endopeptidases; D020169:Caspases
references.citation: Mol Pharmacol. 2006 Aug;70(2):510-7
references.pmid: 16682503
references.citation: Oncogene. 2005 Mar 17;24(12):1973-81
references.pmid: 15674326
references.citation: J Clin Invest. 2010 Oct;120(10):3578-93
references.pmid: 20852385
references.citation: Annu Rev Biochem. 2009;78:435-75
references.pmid: 19489726
references.citation: Nat Rev Cancer. 2009 Oct;9(10):714-23
references.pmid: 19730431
references.citation: Apoptosis. 2009 Jun;14(6):771-7
references.pmid: 19408126
references.citation: Gene Ther. 2000 Jun;7(12):1063-6
references.pmid: 10871756
references.citation: Trends Mol Med. 2003 Jun;9(6):251-5
references.pmid: 12829013
references.citation: Oncogene. 2012 Mar 8;31(10):1323-33
references.pmid: 21785463
references.citation: Cancer Res. 2010 Jun 15;70(12):4789-94
references.pmid: 20501843
references.citation: Cancer Res. 1991 Jan 1;51(1):341-8
references.pmid: 1824823
references.citation: Cancer Res. 2007 Dec 1;67(23):11291-9
references.pmid: 18056455
references.citation: Cancer Lett. 2009 Jan 18;273(2):194-200
references.pmid: 18606491
references.citation: J Neurosci. 2005 Feb 23;25(8):2002-9
references.pmid: 15728840
references.citation: Blood. 1992 May 1;79(9):2378-83
references.pmid: 1571549
references.citation: Blood. 1998 May 15;91(10):3734-45
references.pmid: 9573010
references.citation: Nature. 1995 Oct 19;377(6550):591-4
references.pmid: 7566171
references.citation: Biochem J. 2005 Aug 15;390(Pt 1):359-66
references.pmid: 15833084
references.citation: Cell Cycle. 2009 Dec 15;8(24):4032-9
references.pmid: 19923896
references.citation: Blood. 2009 Dec 3;114(24):5024-33
references.pmid: 19828702
references.citation: J Biol Chem. 1995 Sep 1;270(35):20775-80
references.pmid: 7657660
references.citation: Trends Biochem Sci. 2004 Feb;29(2):95-102
references.pmid: 15102436
references.citation: Nat Rev Cancer. 2007 Sep;7(9):673-83
references.pmid: 17721432
references.citation: Cancer Res. 2009 May 1;69(9):3927-36
references.pmid: 19366808
references.citation: Nat Rev Drug Discov. 2011 Feb;10(2):127-40
references.pmid: 21283107
references.citation: Mol Cell Biol. 1991 Oct;11(10):4895-902
references.pmid: 1656216
references.citation: Oncogene. 2007 Oct 11;26(46):6630-40
references.pmid: 17486076
references.citation: Curr Opin Genet Dev. 2007 Feb;17(1):8-14
references.pmid: 17208428
references.citation: J Neurosci. 2004 Nov 3;24(44):9993-10002
references.pmid: 15525785
references.citation: Mol Cell Biol. 2002 May;22(10):3316-26
references.pmid: 11971965
references.citation: J Cell Physiol. 2006 Oct;209(1):21-43
references.pmid: 16741904
references.citation: J Cell Sci. 2007 Aug 15;120(Pt 16):2935-43
references.pmid: 17666435
references.citation: Bioorg Med Chem Lett. 2003 May 5;13(9):1581-4
references.pmid: 12699760
references.citation: Oncogene. 2009 Aug 27;28(34):3069-80
references.pmid: 19543316
references.citation: J Biol Chem. 2011 Sep 2;286(35):30263-30273
references.pmid: 21768087
references.citation: Oncogene. 2007 May 10;26(21):2975-87
references.pmid: 17130834
references.citation: Clin Cancer Res. 2008 Feb 1;14(3):788-96
references.pmid: 18245540
references.citation: Cell. 2009 Sep 4;138(5):838-54
references.pmid: 19737514
references.citation: Mol Cell Biol. 1998 Jul;18(7):3871-9
references.pmid: 9632771
references.citation: Bioorg Med Chem Lett. 2002 Apr 22;12(8):1219-23
references.pmid: 11934592
references.citation: Apoptosis. 2010 May;15(5):608-20
references.pmid: 20094798
references.citation: N Engl J Med. 2005 Apr 28;352(17):1779-90
references.pmid: 15858187